Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Demanding Focus Of US FDA’s Antiviral, Other Divisions

Executive Summary

Office of New Drugs Director Peter Stein said in an interview that a large amount of coronavirus-related work is arriving at the FDA, but so far staff are keeping up.

You may also be interested in...



2020 In Review: US FDA New Drug Office’s COVID-19 Response Aided By Reorganization

Office of New Drugs Director Peter Stein tells the Pink Sheet that last phase of massive reorg was complicated by pandemic restrictions that forced review staff to work remotely, but the structural overhaul resulted in smaller, more nimble review groups and the breaking down of silos that ultimately helped the agency’s response to the public health crisis.

If Drug Distributors Can Coordinate Without Anti-Trust Concerns During The Coronavirus Pandemic, What About Generic Manufacturers?

Experts and stakeholders suggest it may help avoid drug shortages, but also indicate the interaction, which in normal times would raise anti-trust concerns, may not be needed, even to fight coronavirus.

Drug Distributors Mitigate Coronavirus

For most patients, drug distributors – companies that provide, control and manage drug supplies – operate as an unseen but critical link in the supply chain. In the context of a global pandemic, however, drug distributors play an even bigger role in helping to ensure that pharmacies, health systems and ultimately patients have access to essential medicines.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS141958

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel